Drug Shortage

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can meet present and future demand, Novo Nordisk and the FDA announced.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

The FDA has confirmed there is no longer a shortage of tirzepatide and has set dates for companies to cease distribution of compounded forms of the agent, according to an announcement from the agency.

The FDA announced that tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, has been removed from its drug shortage list.

Shortages of tirzepatide, a GIP/GLP-1 dual agonist approved for the treatment of type 2 diabetes and obesity, have been resolved, the FDA announced.

Findings presented at ASCO Quality Care Symposium provided new insights into the effects last year’s cisplatin shortage had on patients with head and neck cancer.

Two common platinum-based chemotherapies that had been in short supply for most of the past year are much more widely available this summer, according to results of a new National Comprehensive Cancer Network survey.

According to Ashley L. Sumrall, MD, there’s not a great deal of difference between a practicing oncologist and a physician advocate.

A National Comprehensive Cancer Network Annual Conference plenary session examined the impact of drug shortages on oncology care, as well as potential solutions.

To address ongoing chemotherapy drug shortages, ASCO convened a multidisciplinary panel of oncologists, ethicists and patient advocates to expedite clinical guidance for navigating care where rationing or alternative therapies are needed.